ScholarIQanswers from OpenAlex
National Institute of Oncology
InstitutionResearch output, impact & collaborations
National Institute of Oncology is a institution indexed in ScholarIQ from OpenAlex.
What is known about National Institute of Oncology?
ScholarIQrecord summary
National Institute of Oncology is a research organisation in Budapest, HU. OpenAlex records 6,246 works and 335,367 citations for it. 2,066 researchers list it as their most recent affiliation.
How many works does National Institute of Oncology have?
ScholarIQindexed works
National Institute of Oncology has 6,246 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does National Institute of Oncology have?
ScholarIQcitation count
National Institute of Oncology has 335,367 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at National Institute of Oncology?
ScholarIQresearcher count
National Institute of Oncology has 2,066 researchers in the ScholarIQ index.
What is the average h-index at National Institute of Oncology?
ScholarIQavg h-index
National Institute of Oncology has an average h-index of 61.4 in OpenAlex.
What is the ROR of National Institute of Oncology?
ScholarIQror
The ROR for National Institute of Oncology is on the source record.
What is the OpenAlex record for National Institute of Oncology?
ScholarIQopenalex
The OpenAlex for National Institute of Oncology is on the source record.
Who are the most-cited researchers behind National Institute of Oncology?
ScholarIQtop researchers by citations
What are the most-cited papers on National Institute of Oncology?
ScholarIQmost cited works
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie R. Brahmer, Karen L. Reckamp, Paul Baas, Lucio Crinò, Wilfried Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Płużański, Everett E. Vokes, Esther Holgado, David Waterhouse, Neal Ready, Justin F. Gainor, Osvaldo Arén Frontera, Libor Havel, Martin Steins, Marina Chiara Garassino, Joachim G.J.V. Aerts, Manuel Dómine, Luis Paz‐Ares, Martin Reck, Christine Baudelet, Christopher Harbison, Brian Lestini, David R. Spigel
The Multimodal Brain Tumor Image Segmentation Benchmark (BRATS)
Bjoern Menze, András Jakab, Stefan Bauer, Jayashree Kalpathy–Cramer, Keyvan Farahani, Justin Kirby, Yuliya Burren, Nicole Porz, Johannes Slotboom, Roland Wiest, Levente Lánczi, Elizabeth R. Gerstner, Marc‐André Weber, Tal Arbel, Brian Avants, Nicholas Ayache, Patricia Buendia, D. Louis Collins, Nicolas Cordier, Jason J. Corso, Antonio Criminisi, Tilak Das, Hervé Delingette, Çağatay Demiralp, Christopher R. Durst, Michel Dojat, Senan Doyle, Joana Festa, Florence Forbes, Ezequiel Geremia, Ben Glocker, Polina Golland, Xiaotao Guo, Andaç Hamamcı, Khan M. Iftekharuddin, Raj Jena, Nigel John, Ender Konukoğlu, Danial Lashkari, José Mariz, Raphael Meier, Sérgio Pereira, Doina Precup, Stephen J. Price, Tammy Riklin Raviv, Syed M. S. Reza, Michael J. Ryan, Duygu Sarıkaya, Lawrence H. Schwartz, Hoo-Chang Shin, Jamie Shotton, Carlos A. Silva, Nuno Sousa, Nagesh K. Subbanna, Gábor Székely, Thomas J. Taylor, Owen Thomas, Nicholas J. Tustison, Gözde Ünal, Flor Vasseur, Max Wintermark, Dong Hye Ye, Liang Zhao, Binsheng Zhao, Darko Zikic, Marcel Prastawa, Mauricio Reyes, Koen Van Leemput
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
Leora Horn, Aaron S. Mansfield, Aleksandra Szczęsna, Libor Havel, Maciej Krzakowski, Maximilian J. Hochmair, Florian Huemer, György Losonczy, Melissa L. Johnson, Makoto Nishio, Martin Reck, Tony Mok, Sivuonthanh Lam, David S. Shames, Juan Liu, Beiying Ding, Ariel López-Chávez, Fairooz F. Kabbinavar, Wei Lin, Alan Sandler, Stephen V. Liu
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
Matthew D. Hellmann, Tudor–Eliade Ciuleanu, Adam Płużański, Jong Seok Lee, Gregory A. Otterson, Clarisse Audigier-Valette, Elisa Minenza, Helena Linardou, Sjaak A. Burgers, Pamela Salman, Hossein Borghaei, Suresh S. Ramalingam, Julie R. Brahmer, Martin Reck, Kenneth J. O’Byrne, William J. Geese, George Green, Chang Han, Joseph D. Szustakowski, Prabhu Bhagavatheeswaran, Diane Healey, Yali Fu, Faith E. Nathan, Luis Paz‐Ares
Interleukin-1 polymorphisms associated with increased risk of gastric cancer
Emad El‐Omar, Mary Carrington, Wong-Ho Chow, Kenneth E.L. McColl, Jay H. Bream, Howard A. Young, Jesús Herrera, Jolanta Lissowska, Chiu-Chin Yuan, N. Rothman, George Lanyon, Maureen P. Martin, J F Fraumeni, Charles S. Rabkin
How much of the research on National Institute of Oncology is open access?
ScholarIQopen access share
83%OPEN ACCESS